AYTU · Aytu Biopharma, Inc
$2.38
+0.08 (+3.48%)
At close · Aug 14
Market Cap
$25.55M
Shares
10.73M
Aytu Biopharma, Inc Earnings Call Transcripts
Every quarterly earnings call for Aytu Biopharma, Inc (AYTU) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲16.9%
$27.45M
−$16.09M
'22 Q4
22-09-28
▲26.3%
$27.66M
−$701,000
'23 Q1
22-11-14
▲13.6%
$26.28M
−$6.69M
'23 Q2
23-02-21
▼6.1%
$22.73M
−$7.20M
'23 Q3
23-05-11
▲12%
$30.73M
−$2.46M
'23 Q4
23-09-27
▼35.6%
$17.82M
−$8.12M
'24 Q1
23-11-14
▼28.7%
$18.75M
−$220,000
'24 Q2
24-02-14
▼38.3%
$14.03M
−$2.89M
'24 Q3
24-05-15
▼52.5%
$14.59M
−$4.62M
'24 Q4
24-09-26
▼7%
$16.57M
$1.47M
'25 Q1
24-11-13
▼13.5%
$16.22M
$788,000
'25 Q2
25-02-12
▲31.6%
$18.45M
$3.99M
'25 Q3
25-05-14
▲3.7%
$15.13M
−$19.82M
'25 Q4
25-09-23
▼16.2%
$13.89M
$1.97M
'26 Q1
25-11-13
▼6.5%
$15.16M
−$10.58M
'26 Q2
26-02-03
LATEST
▼32.7%
$12.41M
−$5.62M
'26 Q3
26-05-13
Earnings call
FY26 · Q3
2026-05-13
Aytu Biopharma, Inc Q3 FY2026 Earnings Call
Revenue
$12.41M
▼ 32.7% YoY Diluted EPS
$-0.53
▼ 352.4% YoY Gross margin
61.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-02-03
Aytu Biopharma, Inc Q2 FY2026 Earnings Call
Confident tone
ExuA Launch (MDD)
Patient / Consumer Demand Signals
Mechanism / Clinical Differentiation
Revenue
$15.16M
▼ 6.5% YoY Diluted EPS
$-1.05
Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2025-11-13
Aytu Biopharma, Inc Q1 FY2026 Earnings Call
Revenue
$13.89M
▼ 16.2% YoY Diluted EPS
$-0.08
Gross margin
66.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-09-23
Aytu Biopharma, Inc Q4 FY2025 Earnings Call
Confident tone
ExuA Launch and Market Opportunity
ADHD and Pediatric Portfolio
Competitive Differentiation vs SSRIs/SNRIs
Revenue
$15.13M*
▲ 3.7% YoY Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-05-14
Aytu Biopharma, Inc Q3 FY2025 Earnings Call
Revenue
$18.45M
▲ 31.6% YoY Diluted EPS
$0.21
Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-02-12
Aytu Biopharma, Inc Q2 FY2025 Earnings Call
Revenue
$16.22M
▼ 13.5% YoY Diluted EPS
$-0.26
Gross margin
66.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2024-11-13
Aytu Biopharma, Inc Q1 FY2025 Earnings Call
Revenue
$16.57M
▼ 7% YoY Diluted EPS
$-0.15
Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-09-26
Aytu Biopharma, Inc Q4 FY2024 Earnings Call
Revenue
$14.59M*
▼ 52.5% YoY Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-05-15
Aytu Biopharma, Inc Q3 FY2024 Earnings Call
Confident tone
ADHD Portfolio Growth
Pediatric Portfolio
Fiscal 2025 Outlook and Re-rating
Revenue
$14.03M
▼ 38.3% YoY Diluted EPS
$-0.52
Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-02-14
Aytu Biopharma, Inc Q2 FY2024 Earnings Call
Revenue
$18.75M
▼ 28.7% YoY Diluted EPS
$-0.04
Gross margin
77.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2023-11-14
Aytu Biopharma, Inc Q1 FY2024 Earnings Call
Revenue
$17.82M
▼ 35.6% YoY Diluted EPS
$-1.48
Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-09-27
Aytu Biopharma, Inc Q4 FY2023 Earnings Call
Revenue
$30.73M*
▲ 12% YoY Gross margin
60.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-05-11
Aytu Biopharma, Inc Q3 FY2023 Earnings Call
Revenue
$22.73M
▼ 6.1% YoY Diluted EPS
$-1.93
Gross margin
56.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-02-21
Aytu Biopharma, Inc Q2 FY2023 Earnings Call
Revenue
$26.28M
▲ 13.6% YoY Diluted EPS
$-2.15
Gross margin
65.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2022-11-14
Aytu Biopharma, Inc Q1 FY2023 Earnings Call
Revenue
$27.66M
▲ 26.3% YoY Diluted EPS
$-0.28
Gross margin
65.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-09-28
Aytu Biopharma, Inc Q4 FY2022 Earnings Call
Revenue
$27.45M*
▲ 16.9% YoY Gross margin
54.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-02-14
Aytu Biopharma, Inc Q2 FY2022 Earnings Call
Revenue
$23.12M
▲ 52.7% YoY Diluted EPS
$-8.74
Gross margin
53.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2021-11-15
Aytu Biopharma, Inc Q1 FY2022 Earnings Call
Revenue
$21.90M
▲ 62% YoY Diluted EPS
$-21.76
Gross margin
56.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-09-27
Aytu Biopharma, Inc Q4 FY2021 Earnings Call
Revenue
$23.48M*
▲ 58% YoY Gross margin
48.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-05-17
Aytu Biopharma, Inc Q3 FY2021 Earnings Call
Revenue
$13.48M
▲ 65.3% YoY Diluted EPS
$-28.20
Gross margin
-3.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-02-11
Aytu Biopharma, Inc Q2 FY2021 Earnings Call
Revenue
$15.15M
▲ 377.1% YoY Diluted EPS
$-14.40
Gross margin
58.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2020-10-06
Aytu Biopharma, Inc Q1 FY2021 Earnings Call
Revenue
$13.52M
▲ 839% YoY Diluted EPS
$-7.00
Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-05-14
Aytu Biopharma, Inc Q3 FY2020 Earnings Call
Revenue
$8.16M
▲ 243% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-02-13
Aytu Biopharma, Inc Q2 FY2020 Earnings Call
Revenue
$3.17M
▲ 76.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2019-09-30
Aytu Biopharma, Inc Q1 FY2020 Earnings Call
Revenue
$1.44M
▲ 0.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts
CIK
1385818
CUSIP
054754858
13F (30d)
37 filings
37 filers
Visit website
Investor relations